AU2018237123B2 - Bruton's tyrosine kinase inhibitors - Google Patents

Bruton's tyrosine kinase inhibitors Download PDF

Info

Publication number
AU2018237123B2
AU2018237123B2 AU2018237123A AU2018237123A AU2018237123B2 AU 2018237123 B2 AU2018237123 B2 AU 2018237123B2 AU 2018237123 A AU2018237123 A AU 2018237123A AU 2018237123 A AU2018237123 A AU 2018237123A AU 2018237123 B2 AU2018237123 B2 AU 2018237123B2
Authority
AU
Australia
Prior art keywords
pyrazin
phenyl
imidazo
pyrrolidin
methoxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018237123A
Other languages
English (en)
Other versions
AU2018237123A1 (en
Inventor
Anhui GAO
Jia Li
Xibin Liao
Zhijian Lu
Yubo ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Baijibugong Pharmaceutical Technology Co Ltd
Original Assignee
Suzhou Baijibugong Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Baijibugong Pharmaceutical Tech Co Ltd filed Critical Suzhou Baijibugong Pharmaceutical Tech Co Ltd
Publication of AU2018237123A1 publication Critical patent/AU2018237123A1/en
Application granted granted Critical
Publication of AU2018237123B2 publication Critical patent/AU2018237123B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018237123A 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors Active AU2018237123B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474686P 2017-03-22 2017-03-22
US62/474,686 2017-03-22
PCT/US2018/023455 WO2018175512A1 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2018237123A1 AU2018237123A1 (en) 2019-10-10
AU2018237123B2 true AU2018237123B2 (en) 2022-08-04

Family

ID=63585694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018237123A Active AU2018237123B2 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Country Status (12)

Country Link
US (3) US11554118B2 (enExample)
EP (1) EP3601264A4 (enExample)
JP (1) JP7219902B2 (enExample)
KR (1) KR102627756B1 (enExample)
CN (1) CN110494433B (enExample)
AU (1) AU2018237123B2 (enExample)
CA (1) CA3055602A1 (enExample)
EA (1) EA201992147A1 (enExample)
IL (1) IL269152B2 (enExample)
MX (1) MX2019011116A (enExample)
WO (1) WO2018175512A1 (enExample)
ZA (1) ZA201906887B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554118B2 (en) * 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors
CN118955506A (zh) 2019-01-18 2024-11-15 杭州邦顺制药有限公司 布鲁顿酪氨酸激酶抑制剂
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020228637A1 (en) 2019-05-10 2020-11-19 Henan Normal University Substituted 1-amino-1h-imidazole-5-carboxamide as bruton's tyrosine kinase inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111471048B (zh) * 2020-04-30 2021-06-15 成都海博为药业有限公司 一种具有含氮桥环、螺环或并环结构的化合物及其用途
CN115073468B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 咪唑并吡嗪类btk抑制剂的制备及用途
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
WO2013010869A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
WO2013102860A1 (en) * 2012-01-04 2013-07-11 Sanofi Therapeutic use of imidazopyridine derivatives
WO2015025025A1 (en) * 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2016106626A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537364A1 (en) * 2003-09-03 2005-03-10 Galapagos Nv Imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use for the preparation of medicament against 5-ht2a receptor-related disorders
PL2526933T3 (pl) * 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US20140221354A1 (en) 2011-03-31 2014-08-07 Emblem Technology Transfer Gmbh IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
GB2513821A (en) * 2011-06-28 2014-11-12 Andrew Levine Speech-to-text conversion
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
AU2012285987C1 (en) 2011-07-19 2016-09-08 Merck Sharp & Dohme B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as Btk- inhibitors
CN104080789B (zh) * 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014114185A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016106652A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
TW201718572A (zh) * 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN106478633A (zh) 2015-08-27 2017-03-08 正大天晴药业集团股份有限公司 一类布鲁顿酪氨酸激酶抑制剂
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
US20170035881A1 (en) 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
WO2017077507A1 (en) 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
ES2878973T3 (es) 2016-06-30 2021-11-19 Hangzhou Bangshun Pharmaceutical Co Ltd Derivado de fenilo de imidazopiridinamina y uso del mismo
EP3492471B1 (en) * 2016-08-17 2020-12-02 Shenzhen TargetRx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
US11554118B2 (en) * 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
WO2013010869A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
WO2013102860A1 (en) * 2012-01-04 2013-07-11 Sanofi Therapeutic use of imidazopyridine derivatives
WO2015025025A1 (en) * 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2016106626A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase

Also Published As

Publication number Publication date
IL269152B2 (en) 2023-11-01
CN110494433B (zh) 2023-03-17
KR20190133199A (ko) 2019-12-02
IL269152B1 (en) 2023-07-01
WO2018175512A1 (en) 2018-09-27
US20210107903A1 (en) 2021-04-15
BR112019019588A2 (pt) 2020-04-22
US20190275037A1 (en) 2019-09-12
EP3601264A1 (en) 2020-02-05
CA3055602A1 (en) 2018-09-27
CN110494433A (zh) 2019-11-22
JP2020511547A (ja) 2020-04-16
JP7219902B2 (ja) 2023-02-09
US11554118B2 (en) 2023-01-17
AU2018237123A1 (en) 2019-10-10
US11974999B2 (en) 2024-05-07
ZA201906887B (en) 2022-03-30
US20210121458A1 (en) 2021-04-29
MX2019011116A (es) 2020-02-05
US10933063B2 (en) 2021-03-02
EA201992147A1 (ru) 2020-02-20
KR102627756B1 (ko) 2024-01-23
EP3601264A4 (en) 2021-03-24
IL269152A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
AU2017208998B2 (en) Bruton's tyrosine kinase inhibitors
US11974999B2 (en) Bruton's tyrosine kinase inhibitors
WO2017066014A1 (en) Bruton's tyrosine kinase inhibitors
AU2013272701A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
AU2019295983B2 (en) Tricyclic compounds
KR20210108433A (ko) 티에노피리디논 화합물
CN121752556A (zh) 降解swi/snf相关基质相关联肌动蛋白依赖性染色质调控因子a亚家族的化合物和药物组合物
KR20240150419A (ko) 아릴설폰아미드 화합물
ES2771151T3 (es) Derivados de piperidina como inhibidor de señalización wnt
BR112019019588B1 (pt) Composto e composição farmacêutica
EA042551B1 (ru) Ингибиторы тирозинкиназы брутона
WO2026039844A1 (en) Stat6 degraders and uses thereof
CN119707930A (zh) 芳香环类化合物及其制法和用途
BR112018014705B1 (pt) Compostos inibidores de tirosina quinase de Bruton e composição farmacêutica
NZ711699A (en) P2x7 modulators
NZ711699B2 (en) P2x7 modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)